Albany, US – DelveInsight has launched a new report on Thymidine Kinase 2 Deficiency Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Thymidine Kinase 2 Deficiency Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Thymidine Kinase 2 Deficiency, historical and forecasted epidemiology as well as the Thymidine Kinase 2 Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Thymidine Kinase 2 Deficiency market report provides current treatment practices, emerging drugs, Thymidine Kinase 2 Deficiency market share of the individual therapies, current and forecasted Thymidine Kinase 2 Deficiency market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Thymidine Kinase 2 Deficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Key benefits of the report
1. Thymidine Kinase 2 Deficiency market report covers a descriptive overview and comprehensive insight of the Thymidine Kinase 2 Deficiency epidemiology and Thymidine Kinase 2 Deficiency market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Thymidine Kinase 2 Deficiency market report provides insights on the current and emerging therapies.
3. Thymidine Kinase 2 Deficiency market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Thymidine Kinase 2 Deficiency market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Thymidine Kinase 2 Deficiency market.
Request for sample pages here -> https://www.delveinsight.com/sample-request/thymidine-kinase-2-deficiency-tk2d-market
TK2d is an enzyme deficiency. It is a genetic disease that is defined by muscle weakness (myopathy), with effects like difficulty breathing, droopy or saggy eyelids, or trouble chewing and swallowing. It can take a long time before a person is diagnosed with TK2d because TK2d is such a rare disease, doctors are just beginning to learn about it.
Some key epidemiological points:-
- Infantile-onset myopathy (42.4%) with severe mitochondrial DNA (mtDNA) depletion, frequent neurological involvement and rapid progression to early mortality (median post-onset survival (POS) 1.00, CI 0.58–2.33 years).
- Childhood-onset myopathy (40.2%) with mtDNA depletion, moderate-to-severe progression of generalized weakness and median POS at least 13 years.
- Late-onset myopathy (17.4%) with mild limb weakness at onset and slow progression to respiratory insufficiency with median POS of 23 years.
Thymidine Kinase 2 Deficiency Treatment is focused on managing the symptoms and patient experiences.
An alternative treatment approach is Gene Therapy. It holds more significant promise for mitochondrial diseases and other genetic disorders but faces several barriers, such as inefficient gene delivery, immune responses, and short-lived effects.
In general, mitochondrial diseases are challenging to diagnose as the symptoms appear like that of other conditions. For instance, symptoms of spinal muscle atrophy (SMA) are a lot like those of TK2 deficiency. The patients are often misdiagnosed due to this reason. To redress the current issues and critical unmet needs, Zogenix is currently working towards this indication to meet the needs of the current TK2 deficiency market. Pipeline drug in clinical development is designed to address this unmet need in the Thymidine Kinase 2 Deficiency treatment.
Thymidine Kinase 2 Deficiency market size shall grow during the forecast period owing to the launch of upcoming therapies. Thymidine Kinase 2 Deficiency market size is expected to increase during the study period.
Drugs covered
1. MT1621
And many others
The key players in Thymidine Kinase 2 Deficiency market are:
1. Zogenix
And many others
Table of contents
1. Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Thymidine Kinase 2 Deficiency Market Overview at a Glance
5. Thymidine Kinase 2 Deficiency Disease Background and Overview
6. TK2 deficiency Epidemiology and Patient Population
7. Country-Wise TK2 deficiency Epidemiology
7.1. United States
7.2. EU-5
7.2.1. Germany
7.2.2. France
7.2.3. Italy
7.2.4. Spain
7.2.5. United Kingdom
7.3. Japan
8. TK2 deficiency Treatment & Medical Practices
8.1. Thymidine Kinase 2 Deficiency Treatment Algorithm
8.2. Thymidine Kinase 2 Deficiency Treatment Guidelines
9. Patient Journey
10. Key Thymidine Kinase 2 Deficiency Emerging Therapies
10.1. Key Cross Competition
10.2. MT1621: Zogenix
11. Attribute Analysis
12. Thymidine Kinase 2 Deficiency Market Size
13.1. United States
13.2. Germany
13.3. France
13.4. United Kingdom
13.5. Spain
13.6. Italy
13.7. Japan
14. Market Drivers
15. Market Barriers
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
Request for sample pages here -> https://www.delveinsight.com/sample-request/thymidine-kinase-2-deficiency-tk2d-market
Related Reports:
Thymidine Kinase 2 Deficiency (TK2D) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Thymidine Kinase 2 Deficiency (TK2D) market.
DelveInsight’s Thymidine Kinase 2 Deficiency (TK2D) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Thymidine Kinase 2 Deficiency (TK2D) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/